Edition:
United States

Neptune Technologies & Bioressources Inc (NEPT.PH)

NEPT.PH on Philadelphia Stock Exchange

0.85USD
18 Aug 2017
Change (% chg)

$-0.03 (-3.41%)
Prev Close
$0.88
Open
$0.86
Day's High
$0.86
Day's Low
$0.85
Volume
4,606
Avg. Vol
893
52-wk High
$1.50
52-wk Low
$0.70

Latest Key Developments (Source: Significant Developments)

Acasti Pharma reports Q1 loss per share c$0.19
Monday, 14 Aug 2017 05:30pm EDT 

Aug 14 (Reuters) - Acasti Pharma Inc -:Acasti Pharma reports first quarter fy 2018 financial results.Q1 loss per share c$0.19.  Full Article

Neptune reports about 45 pct fall in Q1 revenue
Monday, 14 Aug 2017 05:30pm EDT 

Aug 14 (Reuters) - Neptune Technologies & Bioressources Inc :Neptune announces first quarter results.Q1 revenue c$6.5 million versus c$11.8 million.Neptune Technologies & Bioressources Inc qtrly ‍net loss of $1.2 million versus net income of $1.3 million in prior year​.Neptune Technologies - "there exists a material uncertainty that casts substantial doubt about corporation's ability to continue as a going concern".  Full Article

Neptune appoints John Moretz as chairman
Tuesday, 8 Aug 2017 07:10am EDT 

Aug 8 (Reuters) - Neptune Technologies & Bioressources Inc ::Neptune announces resignation of Pierre Fitzgibbon as a director and the appointment of John Moretz as chairman.Neptune Technologies & Bioressources Inc - ‍John Moretz has been appointed chairman of board effective immediately to replace Fitzgibbon​.  Full Article

Acasti Pharma reports Q4 and FY 2017 financial results
Tuesday, 6 Jun 2017 04:30pm EDT 

June 6 (Reuters) - Acasti Pharma Inc ::Acasti Pharma reports fourth quarter and full-year 2017 financial results.Acasti Pharma Inc - ‍net loss for three-month period ended february 28, 2017 was $0.23 loss per share​.  Full Article

Neptune enters commercial distribution joint venture in China with Shanghai Chonghe Marine Industry
Wednesday, 5 Apr 2017 05:00pm EDT 

Neptune Technologies & Bioressources Inc : Neptune enters into commercial distribution joint venture in China with Shanghai Chonghe Marine Industry Co Ltd . Neptune Technologies & Bioressources Inc - shipments of krill oil under joint venture are projected to start in Q1 ending June 30, 2017 .Neptune Technologies & Bioressources Inc - under agreement, Neptune will own a 30 pct interest in joint venture while CMI/Sunline fishery will hold 70 pct.  Full Article

Neptune, Enzymotec reach patent agreement ending all litigation
Monday, 3 Apr 2017 08:00am EDT 

Enzymotec Ltd : Neptune and Enzymotec reach patent agreement ending all litigation . Enzymotec Ltd - Enzymotec to make a one-time payment of us$1.63 million to Neptune . Enzymotec Ltd - Enzymotec grants Neptune a worldwide and royalty-free license to its krill-related patents . Enzymotec Ltd - Neptune extends Enzymotec's worldwide and royalty-free license to its krill-related patents .Enzymotec Ltd - co, Neptune Technologies entered into broad patent cross-licensing agreement, which ends all outstanding litigation between companies.  Full Article

Acasti Pharma announces pricing for its public offering of units
Friday, 10 Feb 2017 04:26pm EST 

Acasti Pharma Inc : Acasti Pharma announces pricing for its public offering of units .Acasti Pharma- entered agency agreement with Echelon Wealth Partners as sole bookrunner, lead agent; agent to offer units for proceeds of C$4.5 million-C$8 million.  Full Article

Neptune to buy 2.4 pct stake in Bluehole
Tuesday, 31 Jan 2017 02:58am EST 

Neptune Company <217270.KQ> : Says it will buy 166,666 shares in Bluehole, which is engaged in online and mobile game development, to secure strategic partnership . Says transaction amount is 5 billion won .Says it will hold 2.4 percent stake(166,666 shares) in Bluehole after the transaction.  Full Article

Acasti Pharma Q3 loss C$0.22/shr
Thursday, 12 Jan 2017 05:15pm EST 

Acasti Pharma Inc : Acasti Pharma reports third quarter 2017 financial results . Q3 loss per share C$0.22 . Acasti pharma - Had cash,short-term investments of $5.8 million as of Nov 30, 2016 .Acasti Pharma - if co doesn't raise additional funds, there exists material uncertainty casting substantial doubt about ability to continue as going concern.  Full Article

Acasti Pharma announces proposed offering of units
Monday, 5 Dec 2016 05:38pm EST 

Acasti Pharma Inc : Acasti Pharma announces proposed offering of units .Acasti Pharma-Received receipt for a preliminary short form prospectus for minimum gross proceeds of CAD$6.5 million, maximum gross proceeds of CAD$10 million.  Full Article

BRIEF-Neptune reports about 45 pct fall in Q1 revenue

* Neptune Technologies & Bioressources Inc qtrly ‍net loss of $1.2 million versus net income of $1.3 million in prior year​